Go to Health Care Provider version
|Advanced Solid Tumor
|12 years and older
|Line of treatment
|Disease relapse or progression
|Routes of Treatment Administration
|RP-6306 (PKMYT1 Inhibitor): Oral
|Last Posted Update
International SponsorRepare Therapeutics
Principal Investigators for Canadian SitesThe Hospital for Sick Children - Dr. Daniel Morgenstern
The purpose of this study is to find the highest dose of the investigational drug RP-6306 that can be used in advanced solid tumors containing certain genetic changes and which have come back or continued to grow despite prior treatment.
RP-6306 blocks the protein PKMY1, which plays a major role in the survival and growth of cancers with the genetic changes being studied in this clinical trial. RP-6306 is taken orally (by mouth).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have a locally advanced or metastatic solid tumor that has come back or continued to grow despite prior treatment
- Participants’ tumors must contain a mutation in the FBXW7 or PPP2R1A genes or extra copies of the CCNE1 gene
- Patients must be able to walk and do routine activities for more than half of their normal waking hours
- This study is for people age 12 and older
Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team.